SAHPRA Approves Pfizer’s Paxlovid COVID-19 Treatment
SAHPRA announced the registration of Paxlovid COVID-19 treatment, an anti-viral medicine manufactured by Pfizer, to treat COVID-19. This is a 5-day oral treatment for mild to moderate COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.
International sources provide guidelines regarding prescribing in liver and kidney disease as well as possible drug interactions including statin therapy, anticoagulation and some hormonal birth control treatments.
Recent Posts
Transforming Clinical Skill Assessment with Intelligent Evaluation Systems
Clinical skill assessment has long been hampered by subjective judgments and variability among examiners. A novel unified intelligent framework replaces these manual observations with contrastive learning to deliver objective, trace...
Advancing Medical AI through Federated Generative Learning
Federated Generative Learning is emerging as a practical breakthrough for multi-center medical image analysis, simultaneously tackling communication overhead, data scarcity, and institutional heterogeneity. The framework trains a shared prompt generator that produces individualized visual prompts...
Prioritizing a Comprehensive Medtech Market Access Strategy Through Stakeholder Engagement
An effective medtech market access strategy must begin at the concept stage by simultaneously addressing patient needs, clinical workflows, regulatory requirements, and payer expectations rather than defaulting to FDA clearance as the sole priority. Startups that ignore this broader view risk bui...